FDA Grants Accelerated Approval to Zanidatamab-hrii for Patients with Previously Treated Unresectable or Metastatic HER2-positive Biliary Tract Cancer By Ogkologos - December 17, 2024 218 0 Facebook Twitter Google+ Pinterest WhatsApp Evidence for efficacy is based on the results from the HERIZON-BTC-01 study Source RELATED ARTICLESMORE FROM AUTHOR Patient Guide in Testicular Cancer Now Available Also in Italian Adding 177Lu-PNT2002 to SBRT Significantly Improves PFS in Patients with Oligorecurrent Hormone-Sensitive Prostate Cancer A Short-Course Dose Escalation Strategy Could Improve Ability to Reach Target Dose of Adjuvant Abemaciclib in High-Risk Early-Stage HR-positive, HER2-negative Breast Cancer MOST POPULAR Liquid Biopsies for Cancer: What to Know and What to Expect November 3, 2022 Mom Battling Cancer Lets 4-Yr-Old Give Her “Best Haircut Ever.” December 6, 2019 Supplemental Breast Cancer Imaging Techniques Could Lead to Earlier Detection of... May 28, 2025 EMA Recommends Granting a Marketing Authorisation for Ripretinib for the Treatment... October 5, 2021 Load more HOT NEWS Perioperative Durvalumab Plus Neoadjuvant Chemotherapy Results in Greater EFS and pCR... Longer PFS in Patients with Advanced Melanoma Treated with TILs than... FDA Approves Second CAR T-Cell Therapy for Lymphoma Access to Cancer Medicines and Clinical Trials Show Stark Variations Across...
